Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
  • Alerts
  • Podcasts
  • Subscriptions

Nonadherence with inhaled preventer therapy in severe asthmatic patients on long-term omalizumab

David J. Allen, Leanne-Jo Holmes, Kerry A. Hince, Rachael Daly, Calra Ustabashi, Gael Tavernier
European Respiratory Journal 2018 52: 1801025; DOI: 10.1183/13993003.01025-2018
David J. Allen
Severe Asthma Service, Northwest Lung Centre, Wythenshawe Hospital, Manchester, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leanne-Jo Holmes
Severe Asthma Service, Northwest Lung Centre, Wythenshawe Hospital, Manchester, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kerry A. Hince
Severe Asthma Service, Northwest Lung Centre, Wythenshawe Hospital, Manchester, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rachael Daly
Severe Asthma Service, Northwest Lung Centre, Wythenshawe Hospital, Manchester, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Calra Ustabashi
Severe Asthma Service, Northwest Lung Centre, Wythenshawe Hospital, Manchester, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gael Tavernier
Severe Asthma Service, Northwest Lung Centre, Wythenshawe Hospital, Manchester, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Extract

We read with interest the paper by Lee et al. [1], reporting on the high rate of nonadherence in a group of severe asthma patients who were potentially suitable for biological therapy or bronchial thermoplasty. In our experience the issue of nonadherence is not confined to patients under active consideration for biological therapy. We have identified significant rates of nonadherence in a group of patients on long-term Omalizumab therapy.

Abstract

Nonadherence with inhaled preventer therapy is prevalent in previously adherent patients on long-term omalizumab http://ow.ly/5wdE30kp0MM

Footnotes

  • Conflict of interest: D.J. Allen reports non-financial support from Mundipharma for attendance at the ERS meeting, and speaker fees for presenting at an educational meeting sponsored by Astra Zeneca, outside the submitted work.

  • Conflict of interest: L-J. Holmes reports personal fees for speaking at conferences from Novartis and TEVA, outside the submitted work.

  • Received May 31, 2018.
  • Accepted June 4, 2018.
  • Copyright ©ERS 2018
View Full Text

INDIVIDUALS

Log in using your username and password

– ERS members: log in with your myERS username and password.
– Other users: log in with the credentials you created when you registered.
Forgot your user name or password?
Forgot your username or password?

LIBRARY USERS

Log in through your institution

If your library has a subscription, you may already be logged in via your IP address. Otherwise you may be able to log in via one of the following routes.
You may be able to gain access using your login credentials for your institution. Contact your library if you do not have a username and password.
If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.
If you think you should have access, please contact your librarian or email journals@ersnet.org

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

CONTACT US

If you have any questions about the ERS publications website, please contact journals@ersnet.org

PreviousNext
Back to top
View this article with LENS
Vol 52 Issue 2 Table of Contents
European Respiratory Journal: 52 (2)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Nonadherence with inhaled preventer therapy in severe asthmatic patients on long-term omalizumab
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Nonadherence with inhaled preventer therapy in severe asthmatic patients on long-term omalizumab
David J. Allen, Leanne-Jo Holmes, Kerry A. Hince, Rachael Daly, Calra Ustabashi, Gael Tavernier
European Respiratory Journal Aug 2018, 52 (2) 1801025; DOI: 10.1183/13993003.01025-2018

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Nonadherence with inhaled preventer therapy in severe asthmatic patients on long-term omalizumab
David J. Allen, Leanne-Jo Holmes, Kerry A. Hince, Rachael Daly, Calra Ustabashi, Gael Tavernier
European Respiratory Journal Aug 2018, 52 (2) 1801025; DOI: 10.1183/13993003.01025-2018
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • The potential impact of azithromycin in IPF
  • Idiopathic interstitial pneumonia or pneumonitis?
  • Idiopathic interstitial pneumonia or pneumonitis?
Show more Agora

Research letters

  • The potential impact of azithromycin in IPF
  • Idiopathic interstitial pneumonia or pneumonitis?
  • Idiopathic interstitial pneumonia or pneumonitis?
Show more Research letters

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Collections
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2019 by the European Respiratory Society